FindTrial
Sign In

The incidence of resistant mechanism among epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients after disease progression of prior treatments

The incidence of resistant mechanism among epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients after disease progression of prior treatments - The incidence of resistant mechanism among epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients after disease progression of prior treatments

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041252
Enrollment
Unknown
Registered
2020-07-29
Start date
2020-07-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Sponsors

Yokohama City University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who analyzed for the resistant mechanism to EGFR-TKI

Exclusion criteria

Exclusion criteria: Patients who excluded from studies

Design outcomes

Primary

MeasureTime frame
Incidence of each resistant mechanisms to EGFR-TKI—

Countries

Japan

Contacts

Public ContactNobuaki Kobayashi

Yokohama City University Department of Pulmonogy

nkobayas@yokohama-cu.ac.jp+81453527962

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026